Receive The Newest Study Notifications

CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001, China's first fully human, full-length anti-PD-L1 antibody, in combination with...

A woman has given birth to a ‘three-parent baby’ in the first ever clinical trial to test the controversial procedure. The 32-year-old Greek woman had four failed IVF attempts before she heard about the trial by Spanish doctors. The Barcelona-based team used a...

Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used...

Consistent reduction in HBV DNA demonstrated with higher inarigivir doses including in high viral burden HBeAg-positive patients 26% HBsAg responder population for all inarigivir doses showed mean HBsAg change of 0.8log10 with a range of 0.5log10 - 1.4log10 Inarigivir...

CStone Pharmaceuticals("CStone"; HKEX: 2616) announced today that the National Medical Products Administration (NMPA) recently approved the initiation of a Phase I/II clinical trial in China evaluating avapritinib, a drug candidate discovered by the company's partner...

Dr. Elizabeth Tanzi to Present Soliton's Cellulite Data at Music City SCALE 2019 Conference in Nashville, TN Soliton, Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from...

Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus...

TYME to Initiate Pivotal Trials for SM-88 in Patients with Metastatic Pancreatic Cancer Tyme Technologies, Inc.  (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that the United States Adopted...

 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the appointment of Fairooz Kabbinavar, M.D., FACP, as senior vice president, clinical development. Dr. Kabbinavar will oversee the advancement of Tocagen's...

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and...

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14,...

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology,...

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal ring designed to...

Demonstrated statistically significant reduction in daily smoking compared to active comparator (p=0.0016) Trial conducted in collaboration with Duke University NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...

Interim safety results and early efficacy signals with HepaStem bode well for subsequent confirmatory trials in ACLF and provide valuable insights for imminent start of clinical evaluation in NASH Promethera Biosciences SA, a global innovator in cell-based medicines...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA ® (ceftolozane and...

GENFIT to Present Additional Data from the Positive Phase 2 Clinical Trial Evaluating Elafibranor in Primary Biliary Cholangitis at the International Liver Congress™ 2019 -- Further analysis shows significant improvements in PBC cholestatic markers such as GGT (-39%...

Almost half of all clinical trials are conducted in countries outside the United States. The globalization of clinical trials requires stronger knowledge and increased efficiencies in the planning and execution stages. Leader of patient recruitment companies, Clinical...

LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has begun enrolling patients in a European Union multi-center clinical study in dry Age-Related Macular...

Stem cells collected from the patient's own bone marrow holds great interest as a potential therapy for osteoarthritis of the knee (KOA) because of their ability to regenerate the damaged cartilage. The results were released today in STEM CELLS Translational...